Genscript Biotech (DE:G51)
FRANKFURT:G51
Total Valuation
Genscript Biotech has a market cap or net worth of €3.13B. The enterprise value is €4.16B.
Market Cap€3.13B
Enterprise Value€4.16B
Share Statistics
Genscript Biotech has 2,188,417,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,188,417,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Genscript Biotech’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is 5.55%.
Return on Equity (ROE)-0.13
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)5.55%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee172.33K
Profits Per Employee-84.51K
Employee Count5,568
Asset Turnover0.20
Inventory Turnover10.26
Valuation Ratios
The current PE Ratio of Genscript Biotech is ―. Genscript Biotech’s PEG ratio is -0.00919.
PE Ratio―
PS Ratio3.60
PB Ratio0.87
Price to Fair Value0.87
Price to FCF14.31
Price to Operating Cash Flow11.05
PEG Ratio-0.00919
Income Statement
In the last 12 months, Genscript Biotech had revenue of 959.53M and earned -532.83M in profits. Earnings per share was -0.25.
Revenue959.53M
Gross Profit553.20M
Operating Income255.25M
Pretax Income-470.53M
Net Income-532.83M
EBITDA317.61M
Earnings Per Share (EPS)-0.25
Cash Flow
In the last 12 months, operating cash flow was 325.52M and capital expenditures -83.84M, giving a free cash flow of 241.69M billion.
Operating Cash Flow325.52M
Free Cash Flow241.69M
Free Cash Flow per Share0.11
Dividends & Yields
Genscript Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.49
52-Week Price Change-6.73%
50-Day Moving Average1.43
200-Day Moving Average1.54
Relative Strength Index (RSI)46.90
Average Volume (3m)31.00
Important Dates
Genscript Biotech upcoming earnings date is Aug 17, 2026, TBA (Confirmed).
Last Earnings DateMar 16, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Genscript Biotech as a current ratio of 1.47, with Debt / Equity ratio of 13.21%
Current Ratio1.47
Quick Ratio1.41
Debt to Market Cap0.14
Net Debt to EBITDA1.10
Interest Coverage Ratio14.74
Taxes
In the past 12 months, Genscript Biotech has paid 61.87M in taxes.
Income Tax61.87M
Effective Tax Rate-0.13
Enterprise Valuation
Genscript Biotech EV to EBITDA ratio is 11.99, with an EV/FCF ratio of 15.75.
EV to Sales3.97
EV to EBITDA11.99
EV to Free Cash Flow15.75
EV to Operating Cash Flow11.70
Balance Sheet
Genscript Biotech has €843.01M in cash and marketable securities with €523.15M in debt, giving a net cash position of €319.86M billion.
Cash & Marketable Securities€843.01M
Total Debt€523.15M
Net Cash€319.86M
Net Cash Per Share€0.15
Tangible Book Value Per Share€1.83
Margins
Gross margin is 57.65%, with operating margin of 26.60%, and net profit margin of -55.53%.
Gross Margin57.65%
Operating Margin26.60%
Pretax Margin-49.04%
Net Profit Margin-55.53%
EBITDA Margin33.10%
EBIT Margin26.60%
Analyst Forecast
The average price target for Genscript Biotech is €2.09, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€2.09
Price Target Upside42.48% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―